Abstract
Introduction: We aimed to evaluate clinical features, prognostic factors, and treatment preferences in patients with non-clear cell renal cell carcinoma (nccRCC). Methods: Patients with metastatic nccRCC were selected from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) database. Clinical features, prognostic factors, and overall survival (OS) outcomes were investigated. Results: A total of 118 patients diagnosed with nccRCC were included in this study. The median age at diagnosis was 62 years (interquartile range: 56–69). Papillary (57.6%) and chromophobe tumors (12.7%) are common histologic subtypes. Sarcomatoid differentiation was present in 19.5% of all patients. When the patients were categorized according to the International Metastatic RCC Database Consortium (IMDC) risk scores, 66.9% of the patients were found to be in the intermediate or poor risk group. Approximately half of the patients (55.9%) received interferon in the first line. At the median follow-up of 53.2 months (95% confidence interval [CI]: 34.7–71.8), the median OS was 19.3 months (95% CI: 14.1–24.5). In multivariate analysis, lung metastasis (hazard ratio [HR]:2.22, 95% CI: 1.23–3.99) and IMDC risk score (HR: 2.35, 95% CI: 1.01–5.44 for intermediate risk; HR: 8.86, 95% CI: 3.47–22.61 for poor risk) were found to be independent prognostic factors. Conclusion: In this study, survival outcomes are consistent with previous studies. The IMDC risk score and lung metastasis are the independent prognostic factors for OS. This is an area that needs research to better treat this group of patients and create new treatment options.
References
1.
Ridge
CA
, Pua
BB
, Madoff
DC
. Epidemiology and staging of renal cell carcinoma
. Semin Intervent Radiol
. 2014
;31
(1
):3
–8
. https://doi.org/10.1055/s-0033-1363837.
2.
Ferlay
J
, Soerjomataram
I
, Dikshit
R
, Eser
S
, Mathers
C
, Rebelo
M
, . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012
. Int J Cancer
. 2015
;136
(5
):E359
–86
. https://doi.org/10.1002/ijc.29210.
3.
Moch
H
, Cubilla
AL
, Humphrey
PA
, Reuter
VE
, Ulbright
TM
. The 2016 WHO classification of tumours of the urinary system and male genital organs-Part A: renal, penile, and testicular tumours
. Eur Urol
. 2016
;70
(1
):93
–105
. https://doi.org/10.1016/j.eururo.2016.02.029.
4.
National Comprehensive Cancer Network
. NCCN clinical practice guidelines in oncology-kidney cancer. V.3.2022
. National Comprehensive Cancer Network
; 2021
. https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf.
5.
Armstrong
AJ
, Halabi
S
, Eisen
T
, Broderick
S
, Stadler
WM
, Jones
RJ
, . Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
. Lancet Oncol
. 2016
;17
(3
):378
–88
. https://doi.org/10.1016/S1470-2045(15)00515-X.
6.
Tannir
NM
, Jonasch
E
, Albiges
L
, Altinmakas
E
, Ng
CS
, Matin
SF
, . Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial
. Eur Urol
. 2016
;69
(5
):866
–74
. https://doi.org/10.1016/j.eururo.2015.10.049.
7.
Pal
SK
, Tangen
C
, Thompson
IM
Jr, Balzer-Haas
N
, George
DJ
, Heng
DYC
, . A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial
. Lancet
. 2021
;397
(10275
):695
–703
. https://doi.org/10.1016/S0140-6736(21)00152-5.
8.
McDermott
DF
, Lee
JL
, Ziobro
M
, Suarez
C
, Langiewicz
P
, Matveev
VB
, . Open-Label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma
. J Clin Oncol
. 2021
;39
(9
):1029
–39
. https://doi.org/10.1200/JCO.20.02365.
9.
Motzer
RJ
, Bacik
J
, Mariani
T
, Russo
P
, Mazumdar
M
, Reuter
V
. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology
. J Clin Oncol
. 2002
;20
(9
):2376
–81
. https://doi.org/10.1200/JCO.2002.11.123.
10.
Fernandez-Pello
S
, Hofmann
F
, Tahbaz
R
, Marconi
L
, Lam
TB
, Albiges
L
, . A systematic review and meta-analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carcinoma
. Eur Urol
. 2017
;71
(3
):426
–36
. https://doi.org/10.1016/j.eururo.2016.11.020.
11.
Ahrens
M
, Scheich
S
, Hartmann
A
, Bergmann
L
; IAG-N Interdisciplinary Working Group Kidney Cancer of the German Cancer Society
. Non-clear cell renal cell carcinoma: pathology and treatment options
. Oncol Res Treat
. 2019
;42
(3
):128
–35
. https://doi.org/10.1159/000495366.
12.
Motzer
RJ
, Barrios
CH
, Kim
TM
, Falcon
S
, Cosgriff
T
, Harker
WG
, . Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma
. J Clin Oncol
. 2014
;32
(25
):2765
–72
. https://doi.org/10.1200/JCO.2013.54.6911.
13.
Buti
S
, Bersanelli
M
, Maines
F
, Facchini
G
, Gelsomino
F
, Zustovich
F
, . First-line PAzopanib in NOn-clear-cell renal cArcinoMA: the Italian retrospective multicenter PANORAMA study
. Clin Genitourin Cancer
. 2017
;15
(4
):e609
–14
. https://doi.org/10.1016/j.clgc.2016.12.024.
14.
Jung
KS
, Lee
SJ
, Park
SH
, Lee
JL
, Lee
SH
, Lim
JY
, . Pazopanib for the treatment of non-clear cell renal cell carcinoma: a single-arm, open-label, multicenter, phase II study
. Cancer Res Treat
. 2018
;50
(2
):488
–94
. https://doi.org/10.4143/crt.2016.584.
15.
De Giorgi
U
, Carteni
G
, Giannarelli
D
, Basso
U
, Galli
L
, Cortesi
E
, . Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme
. BJU Int
. 2019
;123
(1
):98
–105
. https://doi.org/10.1111/bju.14461.
16.
McGregor
BA
, McKay
RR
, Braun
DA
, Werner
L
, Gray
K
, Flaifel
A
, . Results of a multicenter phase II study of atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and/or sarcomatoid features
. J Clin Oncol
. 2020
;38
(1
):63
–70
. https://doi.org/10.1200/JCO.19.01882.
17.
Chahoud
J
, Msaouel
P
, Campbell
MT
, Bathala
T
, Xiao
L
, Gao
J
, . Nivolumab for the treatment of patients with metastatic non-clear cell renal cell carcinoma (nccRCC): a single-institutional experience and literature meta-analysis
. Oncologist
. 2020
;25
(3
):252
–8
. https://doi.org/10.1634/theoncologist.2019-0372.
18.
Gupta
R
, Ornstein
MC
, Li
H
, Allman
KD
, Wood
LS
, Gilligan
T
, . Clinical activity of ipilimumab plus nivolumab in patients with metastatic non-clear cell renal cell carcinoma
. Clin Genitourin Cancer
. 2020
;18
(6
):429
–35
. https://doi.org/10.1016/j.clgc.2019.11.012.
19.
Kyriakopoulos
CE
, Chittoria
N
, Choueiri
TK
, Kroeger
N
, Lee
JL
, Srinivas
S
, . Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the international metastatic renal cell carcinoma database Consortium
. Clin Genitourin Cancer
. 2015
;13
(2
):e79
–85
. https://doi.org/10.1016/j.clgc.2014.08.011.
20.
Iacovelli
R
, Ciccarese
C
, Bria
E
, Bracarda
S
, Porta
C
, Procopio
G
, . Patients with sarcomatoid renal cell carcinoma: re-defining the first-line of treatment–a meta-analysis of randomised clinical trials with immune checkpoint inhibitors
. Eur J Cancer
. 2020
;136
:195
–203
. https://doi.org/10.1016/j.ejca.2020.06.008.
21.
Escudier
B
, Molinie
V
, Bracarda
S
, Maroto
P
, Szczylik
C
, Nathan
P
, . Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis
. Eur J Cancer
. 2016
;69
:226
–35
. https://doi.org/10.1016/j.ejca.2016.08.004.
22.
Ravaud
A
, Oudard
S
, De Fromont
M
, Chevreau
C
, Gravis
G
, Zanetta
S
, . First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)
. Ann Oncol
. 2015
;26
(6
):1123
–8
.23.
Kroeger
N
, Xie
W
, Lee
JL
, Bjarnason
GA
, Knox
JJ
, Mackenzie
MJ
, . Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria
. Cancer
. 2013
;119
(16
):2999
–3006
. https://doi.org/10.1002/cncr.28151.
24.
Colomba
E
, Le Teuff
G
, Eisen
T
, Stewart
GD
, Fife
K
, Larkin
J
, . Metastatic chromophobe renal cell carcinoma treated with targeted therapies: a Renal Cross Channel Group study
. Eur J Cancer
. 2017
;80
:55
–62
. https://doi.org/10.1016/j.ejca.2017.03.011.
25.
Kim
JK
, Kim
SH
, Song
MK
, Joo
J
, Seo
SI
, Kwak
C
, . Survival and clinical prognostic factors in metastatic non-clear cell renal cell carcinoma treated with targeted therapy: a multi-institutional, retrospective study using the Korean metastatic renal cell carcinoma registry
. Cancer Med
. 2019
;8
(7
):3401
–10
. https://doi.org/10.1002/cam4.2222.
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.
